With the in-depth development of a new round of scientific and technological revolution and industrial transformation, the global life sciences are changing with each passing day, biotechnology is accelerating iteration, and the biomedical industry has begun to enter a high-growth channel
.
In China, affected by the continuous introduction of favorable biomedical policies, the biomedical industry is also achieving rapid development
.
Statistics show that as of 2021, the market size of China's biopharmaceutical industry has reached 3.
97 trillion yuan, and it is expected that the market size of China's biopharmaceutical industry is expected to exceed 4 trillion yuan
by 2023.
It is worth noting that at present, domestic pharmaceutical companies are accelerating their entry into the biopharmaceutical market
.
Among them, many enterprises are accelerating the improvement of biomedical innovation capabilities
by building biomedical innovation projects and building production bases.
For example, recently, Yiqiao Shenzhou issued an announcement that the company intends to sign the "Entering the Zone Agreement" with the Beijing Economic and Technological Development Zone Management Committee, purchase land use rights and house ownership according to the agreement, the company will build Yiqiao Shenzhou Biomedical Innovation Public Service Platform and Achievement Transformation Base Project in the development zone, the total investment amount of the project is not less than 1 billion yuan, the main construction content of the project is to create a one-stop biological reagent and technical service platform, build a biomedical innovation service-oriented comprehensive park, and the project will reach production within two years from the date of production.
Production
is expected to reach in 2025.
It is reported that Yiqiao Shenzhou signed the "Entry Agreement" with the Beijing Economic and Technological Development Zone Management Committee this time, which is conducive to win-win cooperation and common development
between the two sides.
If the project is successfully constructed, it will help optimize the company's production and operation environment, maintain the stability of production and operation, expand the scale of production and operation, enhance the company's core competitiveness and comprehensive competitiveness, and benefit the company's long-term development
.
Prior to this, Ascentage Pharma's first Ascentage Innovative Drug High-quality Development Ecological Summit and Ascentage Pharma's Global Industrial Base and Innovation Factory Opening Ceremony were also successfully held
in Suzhou.
This is another major milestone
for Ascentage Pharma following the opening of Ascentage Pharma's global headquarters and R&D center in Suzhou in December 2021.
According to public information, Ascentage Pharma's global industrial base is located in the global headquarters park of Ascentage Pharma, and the annual production capacity of oral solid dosage forms is currently 250 million tablets or capsules, which can meet the production needs
of clinical samples and commercial drugs at different stages.
The Company is conducting a blockbuster product in key registration clinical trials with the Bcl-2 selective inhibitor APG-2575 tablet, followed by clinical sample production, registration lot and process validation batch production and future commercial manufacturing
at the industrial site.
It is worth mentioning that the official launch of the global industrial base means that Ascentage Pharma can meet the R&D and production needs
of the whole chain of new drugs from preclinical to clinical, from IND to NDA, and from small-scale trial to commercialization.
In addition, on August 30, Hualan Biotech also said on the investor interactive platform that Hualan Biomedical R&D and intelligent production base has started construction
.
The base will meet the capacity demand of human albumin, intravenous human immunoglobulin and other products, and the company is expected to further improve the industrial layout and enhance its core competitiveness
after expanding the production scale.
According to the data, Hualan Biomedical R&D and intelligent production base covers an area of 351 mu, with a total planned investment of 3 billion yuan, which will be implemented
in three phases.
After the completion of the first phase of the project, it will become a large-scale intelligent blood product production base
in China.
The first phase of the project plans to invest 1.
5 billion yuan to build intelligent blood product production workshops, R&D, quality inspection centers and other supporting facilities, which can achieve an annual output value of 5 billion yuan
after completion.
From the above, it is obvious that pharmaceutical companies are optimistic
about investment opportunities in the biomedical field.
In fact, in addition to building an innovative production base in the biomedical industry, pharmaceutical companies are also keen to participate in funds and financing to increase investment in the biomedical field
.
On November 2, OPCOM announced that OPPLE Investment, a wholly-owned subsidiary of the company, intends to invest RMB 115 million with its own funds to participate in the establishment of the fund Anhui Shanhong Venture Capital Partnership (Limited Partnership).
The fund invests in innovative medical device, biomedical and medical services companies
.
On August 3, Vitelleron announced the completion of a Series B financing, raising a total of US$200 million
.
It plans to use the proceeds for the clinical development of receptor-interacting protein kinase 1 (RIPK1) inhibitors, and further expand the company's R&D scale and pipeline to develop potential best-in-class/best-in-class drug candidates for aging-related degenerative diseases
.
In general, from the continuous release of policies conducive to the development of bio-economy, bio-economy, as one of the main focuses of current economic development, has become the "keyword"
of China's economic and social transformation.
Affected by this, it is expected that those pharmaceutical companies that accelerate the breakthrough of the bottleneck of bio-economic development and provide strong power support for promoting high-quality development by continuously building national biotechnology strategic scientific and technological strength are also destined to usher in more development opportunities
in the future.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
